Quintuple GLP-1R-GIPR-PPAR Agonism Improves Mouse Metabolism

Key Takeaways

• In mouse models, a novel “quintuple agonist” combiningGLP-1 and GIP receptor activation with triple PPAR (α/γ/δ) agonism outperformed semaglutide and GLP-1/GIP co-agonism in reducing body weight, food intake, and blood glucose.
• Safety findings in mice were encouraging within assessed endpoints, with no observed signals of fluid retention, renal impairment, or tissue pathology.

A newly engineered “quintuple agonist” targeting both incretin and nuclear receptor pathways may represent a next-generation therapeutic approach for obesity and type 2 diabetes, according to a recent study published in Nature. By integrating GLP-1 and GIP receptor activity with triple PPAR agonism, the therapy demonstrated substantial metabolic improvements in preclinical models, outperforming semaglutide and GLP-1/GIP co-agonism in mouse models.

The investigational compound—referred to as GLP-1–GIP–lanifibranor (GLP-1–GIP–Lani)—is designed to combine the anorectic and glucose-lowering effects of incretin hormones with the insulin-sensitizing and anti-inflammatory properties associated with activation of PPARα, PPARγ, and PPARδ. Notably, the molecule facilitates targeted delivery of the PPAR agonist to cells expressing GLP-1 or GIP receptors, which may enhance therapeutic efficacy while limiting systemic exposure.

In vitro, the agent demonstrated receptor signaling and insulinotropic activity comparable to established GLP-1/GIP co-agonists. In vivo, however, its effects were more pronounced. In diet-induced obese mouse models, GLP-1–GIP–Lani resulted in greater reductions in body weight, caloric intake, and blood glucose compared with semaglutide or GLP-1/GIP dual agonism alone. These effects were accompanied by improvements in insulin sensitivity and suppression of hepatic glucose production, both of which are central to glycemic regulation.

Mechanistic analyses suggest a synergistic interaction between incretin receptor signaling and PPAR-mediated pathways. While GLP-1 and GIP signaling primarily influence appetite regulation and insulin secretion, PPAR activation appears to modulate peripheral metabolic processes, including lipid metabolism and inflammatory signaling. Transcriptomic profiling identified broad gene expression changes across hepatic, adipose, and skeletal muscle tissues, particularly within pathways related to energy homeostasis and inflammation.

Safety findings in mouse models were favorable within the scope of evaluated endpoints. Treatment was associated with improvements in hepatic parameters, reductions in triglyceride accumulation, and enhanced cardiac function, without these signals in the assessed mouse studies—adverse effects historically associated with PPAR agonism, such as fluid retention or renal impairment.

The observed effects were mechanistically supported. Disruption of GLP-1R, GIPR, or PPARδ signaling attenuated the therapeutic response, confirming roles for GLP-1R, GIPR, and PPARδ signaling in mediating the compound’s metabolic effects. Importantly, improvements in glycemic control were observed even when weight loss was matched between treatment groups, suggesting partially weight-independent mechanisms.

Despite these findings, translational applicability remains to be established. The data are limited to rodent models, and the complexity of simultaneously targeting five receptor pathways introduces considerations related to safety, tolerability, and manufacturability in humans. Further studies will be required to delineate the contribution of each receptor pathway and to assess long-term outcomes.